Cargando…

Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia

Background: Idiopathic inflammatory myopathies (IIMs) are rare systemic diseases associated with significant morbidity and mortality. The aim of our study was to estimate for the first time the survival of IIM patients in Slovenia. Methods: We included IIM patients diagnosed between January 2005 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hočevar, Alojzija, Viršček, Andrej, Krošel, Monika, Gradišnik, Suzana, Rotar, Žiga, Tomšič, Matija, Holc, Iztok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720883/
https://www.ncbi.nlm.nih.gov/pubmed/34988103
http://dx.doi.org/10.3389/fmed.2021.801078
_version_ 1784625220672290816
author Hočevar, Alojzija
Viršček, Andrej
Krošel, Monika
Gradišnik, Suzana
Rotar, Žiga
Tomšič, Matija
Holc, Iztok
author_facet Hočevar, Alojzija
Viršček, Andrej
Krošel, Monika
Gradišnik, Suzana
Rotar, Žiga
Tomšič, Matija
Holc, Iztok
author_sort Hočevar, Alojzija
collection PubMed
description Background: Idiopathic inflammatory myopathies (IIMs) are rare systemic diseases associated with significant morbidity and mortality. The aim of our study was to estimate for the first time the survival of IIM patients in Slovenia. Methods: We included IIM patients diagnosed between January 2005 and December 2020 and followed at two secondary/tertiary rheumatology centers in the country. To study survival/mortality the censor date of April 14 2021 was set. Kaplan–Meier analysis and standardized mortality ratio (SMR) were plotted using data of age and sex matched Slovenian population as a reference. Cox proportional hazards regression analysis was used to study prognostic factors for IIM mortality. Results: During the 16-year observation period, we identified 217 new IIM patients. During follow up 65 (30.0%) patients died. In the first year following IIM diagnosis the SMR was nearly 7-fold higher compared to the matched general population [SMR 6.88 (95%CI 4.41–10.24)] and remained higher also during the following 4 years. However, when excluding IIM patients with cancer, the survival outcome was, except in the first year after IIM diagnosis [SMR 5.55 (95%CI 3.10–9.15)], comparable to matched general population. In addition to cancer [HR 3.71 (95% CI 2.18–6.04)], cardiac involvement [HR 2.18 (95% CI 1.07–4.45)], fever [HR 2.13 (95% CI 1.13–4.03)], and older age [HR 1.07 (95% CI 1.04–1.09)] were extracted as prognostic factors associated with death. Conclusion: The survival of patients with IIM patients was substantially worse compared to matched general population. Cancer was the leading cause of death in our cohort.
format Online
Article
Text
id pubmed-8720883
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87208832022-01-04 Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia Hočevar, Alojzija Viršček, Andrej Krošel, Monika Gradišnik, Suzana Rotar, Žiga Tomšič, Matija Holc, Iztok Front Med (Lausanne) Medicine Background: Idiopathic inflammatory myopathies (IIMs) are rare systemic diseases associated with significant morbidity and mortality. The aim of our study was to estimate for the first time the survival of IIM patients in Slovenia. Methods: We included IIM patients diagnosed between January 2005 and December 2020 and followed at two secondary/tertiary rheumatology centers in the country. To study survival/mortality the censor date of April 14 2021 was set. Kaplan–Meier analysis and standardized mortality ratio (SMR) were plotted using data of age and sex matched Slovenian population as a reference. Cox proportional hazards regression analysis was used to study prognostic factors for IIM mortality. Results: During the 16-year observation period, we identified 217 new IIM patients. During follow up 65 (30.0%) patients died. In the first year following IIM diagnosis the SMR was nearly 7-fold higher compared to the matched general population [SMR 6.88 (95%CI 4.41–10.24)] and remained higher also during the following 4 years. However, when excluding IIM patients with cancer, the survival outcome was, except in the first year after IIM diagnosis [SMR 5.55 (95%CI 3.10–9.15)], comparable to matched general population. In addition to cancer [HR 3.71 (95% CI 2.18–6.04)], cardiac involvement [HR 2.18 (95% CI 1.07–4.45)], fever [HR 2.13 (95% CI 1.13–4.03)], and older age [HR 1.07 (95% CI 1.04–1.09)] were extracted as prognostic factors associated with death. Conclusion: The survival of patients with IIM patients was substantially worse compared to matched general population. Cancer was the leading cause of death in our cohort. Frontiers Media S.A. 2021-12-20 /pmc/articles/PMC8720883/ /pubmed/34988103 http://dx.doi.org/10.3389/fmed.2021.801078 Text en Copyright © 2021 Hočevar, Viršček, Krošel, Gradišnik, Rotar, Tomšič and Holc. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Hočevar, Alojzija
Viršček, Andrej
Krošel, Monika
Gradišnik, Suzana
Rotar, Žiga
Tomšič, Matija
Holc, Iztok
Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia
title Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia
title_full Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia
title_fullStr Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia
title_full_unstemmed Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia
title_short Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia
title_sort survival of patients with idiopathic inflammatory myopathies in slovenia
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720883/
https://www.ncbi.nlm.nih.gov/pubmed/34988103
http://dx.doi.org/10.3389/fmed.2021.801078
work_keys_str_mv AT hocevaralojzija survivalofpatientswithidiopathicinflammatorymyopathiesinslovenia
AT virscekandrej survivalofpatientswithidiopathicinflammatorymyopathiesinslovenia
AT kroselmonika survivalofpatientswithidiopathicinflammatorymyopathiesinslovenia
AT gradisniksuzana survivalofpatientswithidiopathicinflammatorymyopathiesinslovenia
AT rotarziga survivalofpatientswithidiopathicinflammatorymyopathiesinslovenia
AT tomsicmatija survivalofpatientswithidiopathicinflammatorymyopathiesinslovenia
AT holciztok survivalofpatientswithidiopathicinflammatorymyopathiesinslovenia